Novel Immunotherapy for Cancer Treatment: Chimeric Antigen Receptors Targeting CD70 Antigen
Scientists at the NCI's Surgery Branch have developed anti-CD70 chimeric antigen receptors (CARs) to treat cancers. CD70 is an antigen that is expressed on a variety of human cancers such as renal cell carcinoma, glioblastoma, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. The anti-CD70 CARs are hybrid proteins consisting of a receptor portion that recognizes CD70 antigen, and intracellular T cell signaling domains selected to optimally activate the CAR expressing T cells. Genetically engineered T cells that express this CARs will bind to CD70 on the cancer cells and will be activated to induce an immune response that promotes robust tumor cell elimination when infused into cancer patients. This technology can rapidly generate a vigorous T-cell response from the patient's own blood, targeting CD70 expressing cancer cells, and potentially induce tumor rejection.
Competitive Advantages:
- CD70-specific CARs expressed on T cells will increase the likelihood of successful targeted therapy.
- CAR-T cells targeting only CD70 expressing cells and thus may generate fewer side effects than other cancer treatment approaches.
- T-cell transfer can provide much larger numbers of anti-tumor immune cells compared to other approaches such as vaccines.
- With the advent of Provenge(R), and Yervoy(R), immunotherapy is now more widely accepted as a viable cancer treatment option.
Commercial Applications:
- Immunotherapeutics to treat cancers that overexpress CD70, such as renal cell carcinoma, glioblastoma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia.
- A personalized cancer treatment strategy for patients whose tumor cells express CD70 whereby the patient’s own T cells are isolated, engineered to express the anti-CD70 CARs, and re-infused into the same patient to attack the tumor(s).
Patents
- US
Provisional (PRV) 62/088,882
Filed on 2014-12-08
Status: Abandoned - Patent Cooperation Treaty
(PCT) PCT/US2015/025047
Filed on 2015-04-09
Status: Expired - Australia
National Stage 2015361261
Filed on 2015-04-09
Status: Issued - Canada
National Stage 2970280
Filed on 2015-04-09
Status: Pending - China
National Stage 201580066498.4
Filed on 2017-06-07
Status: Issued - European Patent
National Stage 15718065.4
Filed on 2015-04-09
Status: Issued - Japan
National Stage 2017-530742
Filed on 2017-06-08
Status: Issued - US Patent 10,689,456
Filed on 2017-05-30
Status: Issued - European Patent
Divisional (DIV) 19178931.2
Filed on 2019-06-07
Status: Issued - Germany
European patent (EP) 15718065.4
Filed on 2015-04-09
Status: Issued - Spain
European patent (EP) 15718065.4
Filed on 2015-04-09
Status: Issued - France
European patent (EP) 15718065.4
Filed on 2015-04-09
Status: Issued - United Kingdom
European patent (EP) 15718065.4
Filed on 2015-04-09
Status: Issued - Ireland
European patent (EP) 15718065.4
Filed on 2015-04-09
Status: Issued - Italy
European patent (EP) 15718065.4
Filed on 2015-04-09
Status: Issued - Austria
European patent (EP) 15718065.4
Filed on 2015-04-09
Status: Issued - Belgium
European patent (EP) 15718065.4
Filed on 2015-04-09
Status: Issued - Switzerland
European patent (EP) 15718065.4
Filed on 2015-04-09
Status: Issued - Czech Republic
European patent (EP) 15718065.4
Filed on 2015-04-09
Status: Issued - Greece
European patent (EP) 15718065.4
Filed on 2015-04-09
Status: Issued - Liechtenstein
European patent (EP) 15718065.4
Filed on 2015-04-09
Status: Issued - The Netherlands
European patent (EP) 15718065.4
Filed on 2015-04-09
Status: Issued - Norway
European patent (EP) 15718065.4
Filed on 2015-04-09
Status: Issued - Poland
European patent (EP) 15718065.4
Filed on 2015-04-09
Status: Issued - Po